By Doug Macron

Arrowhead Research's top official last week assured investors that the company's acquisition of Alvos Therapeutics would not significantly impact its burn rate, which had already been markedly increased late last year when it acquired the RNA drug assets of Roche.

He also said that the deal is expected to give Arrowhead an edge in its longstanding effort to close a partnership with a bigger industry player, although he declined to provide any guidance on when such an arrangement might be struck.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.